Combined sirtuin and HDAC inhibitors (or FK866 and HDAC inhibitors) showed antileukemic activity against cells of different lineages (primary AML, primary B-CLL, U937, 697, and Jurkat cells), suggesting that such drug combinations may find applications in a broad spectrum of hematological malignancies. The gene discussed is HDAC9; the disease is hematologic disorder.